Authors
- Rushton, Misty
- Clark, Robyn
- Brideson, Genevieve
- Damarell, Raechel
Article Content
Review question
What is the effectiveness of non-pharmacological interventions on the management of cancer treatment-induced cardiotoxicity?
Background
Cardiotoxicity resulting in left ventricular failure is a devastating and most feared outcome of anti-cancer therapy for oncology patients.1 It is possible that a patient may survive cancer only to develop heart failure, which may carry a higher mortality rate than cancer.1 The effects of cardiotoxicity as a result of cancer therapy include myocardial ischemia, hypertension, arrhythmias, thromboembolism, pericarditis and conduction defects which negatively impact on cancer rehabilitation and survivorship require attention.2-7 Of significant concern gaining the attention of cardiologist and oncologists is the development of left ventricular dysfunction (LVD) as a result of singular or concomitant cancer therapies, potentially progressing to heart failure (HF), or even death.2,8,9 Evidence for practice for the management of cardiotoxicity is only just beginning to emerge. To date most studies have examined pharmacological therapies for the management of patients with both cancer and HF. Over the last 50 years, there has been a significant amount of Level 1 evidence (systematic reviews of randomized controlled trails) emerging for the pharmacological and non-pharmacological management of heart failure, and nurses have played a major role in the implementation of non-pharmacological nurse-led strategies. However, to date there is a dearth of literature that looks at the non-pharmacological treatment of cardiotoxicity induced heart failure. Therefore, a good understanding of the potential risk factors and service needs, from early detection and optimal management strategies in the acute and survivor stages could enhance the safety of anti-cancer treatments, and ensure that extended cancer-free survival translates into improved survival and quality of life.
Cardiotoxicity is a general term describing "toxicity that affects the heart".10 International oncological guidelines define cardiotoxicity as "an absolute decrease in left ventricular ejection fraction (LVEF) >10 percent units associated with a decline below its normal limit of 50%".11(p. 2474) Acute, sub-acute and chronic cardiotoxicity may occur in cancer patients as a direct result of the very treatment which aims to improve survival outcomes and can further compromise the clinical effectiveness, applicability and tolerability of cancer therapy.10,34,35,126 Recent data reports that the risk of developing HF secondary to cardiotoxicity is up to 15 times higher in cancer populations when compared to the general population, which substantially increases with age.2,29,80,125-127 Recent figures further report one in four women treated with trastuzumab eventually develop HF resulting from cardiotoxic insult, with varying statistical data for other chemotherapeutic agents varying from 1-5% incidence rates depending on cardiovascular risk factors, cumulative doses and cardiac tolerability of cancer therapy.2,29,80,125-127 The development of HF can potentially compromise cancer survivorship and quality of life independent of the oncological prognosis.11
Heart failure is correlated with a high incidence of morbidity and mortality.12 Characterized by frequent and recurrent hospital admissions, the economic burden for ongoing management is exponential.4,6,13,14 Risk factors that contribute to the development of HF include coronary artery disease, hyper- or hypotension and arrhythmias, and therefore remain the focus for prevention or treatment.4,6 As a complex progressive clinical syndrome, HF results from structural or functional myocyte damage, compromizing the ability of the ventricles to fill with blood or eject blood.15-18 Toxicity to the ventricles from agents such as chemotherapeutic drugs or radiotherapy results in structural and morphological changes to the left ventricle.16,19-21 This process is well recognized by cardiologists as cardiac remodeling.6 As the chamber morphs in size and structure, the haemodynamic stress may temporarily or permanently depress ventricular function.4,6
Typically, patients present with shortness of breath and fatigue, two common clinical manifestations limiting their functional capacity, exercise tolerance and significantly compromising quality of life.6 The development of cardiac rehabilitation programs have proven effective for the management of heart failure to improve survival, quality of life and reduce cardiovascular risks for cardiac sequale.22,23 However, cardiac rehabilitation programs are yet to determine the effects of a bundle of non-pharmacological interventions on the incidence, management or prevention of cardiotoxicity in cancer patients.
Management of heart failure
Cardiac rehabilitation and secondary prevention programs are integral to the comprehensive care and management of patients with HF to improve survival, quality of life and reduce cardiovascular risks for cardiac sequale.14,22-24 With approximately 20% of patients dying in the first year after diagnosis, key management strategies require both pharmacotherapy and non-pharmacological approaches to treat this progressive and potentially fatal condition.18,25,16 The fundamental principles of non-pharmacological cardiac rehabilitation focus on implementing interventions such as exercise, dietary modifications, cessation of smoking, improving psychosocial wellbeing, reducing stress and mortality, with evidence-based practice showing improvements to each component, and contributing to an improved quality of life in individuals with HF.14,22,26
Cancer and cardiotoxicity
Cancer is estimated to be the leading cause of burden for disease for Australia, with more diagnosis of cancer attributed to population growth and the aging population.27 Approximately 60% of cancer patients will survive five years from diagnosis due to medical advancements in multi-modal cancer therapies.28 However, anthracyclines, trastuzumab, high-dose cyclophosphamides and radiotherapy treatments commonly cause decline in ventricular function as a result of cardiac toxicity and can lead to HF.29-32 The incidence rates of cardiotoxicity reported in literature linked to these commonly-prescribed chemotherapy agents are reported at 1-26% with anthracycline,33,34 7-28% with high-dose cyclophosphamides,31,33-35 and 8-30% with trastuzumab.1,34,36,37 However, more than half of patients exposed to anthracyclines develop a degree of cardiac dysfunction up to 20 years post cancer therapy, and anthracycline metabolites can still be detected in cardiomyocytes years after cessation of cancer therapy.11,38
Radiotherapy is one of the primary treatment modalities contributing to cure or palliation.39 When used independently thoracic radiation compromises left ventricular function and advances the development of cardiac disease.40 However, when used in conjunction with chemotherapy, literature reports radiotherapy significantly increases the risk of death from myocardial infarction throughout survivorship.36,40 Cardiac toxicity from chest, breast or oesophageal irradiation is associated with a 22% incidence and women are four times more likely to develop cardiotoxicity, hinting at a gender-bias risk.41-43 Whilst the clinical signs of radiation injury may present immediately after exposure, cardiotoxicity is more likely to occur years to decades after exposure.19,43-45
Radiotherapy effects can be categorized as acute, consequential or late, and cancer patients may clinically present with pericarditis, conduction abnormalities and persistent tachycardia.43,45,46 Breast cancer survivors with left sided chest irradiation are at a higher risk of morbidity and mortality from ischemic heart disease than those exposed to right sided chest irradiation.21,47 Childhood cancer survivors have a greater risk of cardiotoxicity and a higher severity of left ventricular failure when compared to adult survivors with recent cohort studies determining the incidence of HF in this demographic accounts in up to half of cases.48,49 Current research suggests cardioprotective interventions, such as reduction in cardiotoxic agents or cessation of cancer therapy; however, these options must consider the severity of the cancer malignancy.4 Few studies have evaluated the use of pharmacotherapies, such as angiotensin converting enzyme inhibitors (ACEIs), beta-blockers (BBs), angiotensin-receptor blockers (ARBs) or even dexrazoxane, and determine the timing of implementing pharmacological management imminent for cardioprotection.37,50-55 Whilst the results of these studies appear beneficial, they are limited in scope and focus, and are predominantly centered on the benefits of pharmacotherapy protection for this demographic, thus creating an opportunity for further research into the effects of additional non-pharmacological interventions on cardiotoxicity. With a potential lapse in time between exposure to cancer therapy and the development of cardiotoxicity, research that determines the effects of non-pharmacological interventions for prevention or management of HF for these patients is yet to exist.125
Cancer survivorship and rehabilitation
The term "survivorship" is a dynamic new concept for cancer patients mainly attributed to revolutionary medical advancements and oncological treatments.40 Similarly, the concept of cancer rehabilitation has evolved as a result of increased incidence of cancer patients living beyond their diagnosis and predicted life-expectancy.56 The primary focus of cancer rehabilitation programs is to prolong active life expectancy independently of the oncological diagnosis or prognosis. In European countries, cancer rehabilitation occurs predominantly as out-patient programs for up to three weeks tailored to the specific needs of the patient.56 In Australia, non-pharmacological strategies to improve outcomes in these patients requires investigation into the acute and survivor stages, and could enhance the safety of anticancer treatments and ensure that extended cancer-free survival translates to improved survival and quality of life.
Improved survival rates are accompanied by significantly debilitating cancer-related side effects such as cardiotoxicity, fatigue, decreased cardiopulmonary capacity, impaired or reduced physical activity capability, reduction in nutritional intake and overall reduction in quality of life (QOL).57-59 As these aspects have significantly an adverse impact on the functional capacity of cancer survivors, they clearly illustrate that cancer rehabilitation programs which target the holistic and individual needs of cancer survivors are an integrated and contributory concept in survivorship, for which further research is necessary.
Management of cardiotoxicity
There is a magnitude of literature which consistently identifies the link between cancer therapy and cardiotoxicity and further demonstrates comparable mortality rates between HF and cancer.60,61 Currently, the National Heart Foundation recommends screening, treatment and follow-up of cardiac disease in cancer patients; however, universally accepted guidelines for short and long term care of cancer cardiotoxicity are currently lacking.121 Considering the exponential expansion of the incidence of cancer and cancer survivorship, the development of universally accepted evidence-based practice guidelines is integral for the management of cardiotoxic cancer survivors.
For heart failure patients, cardiac rehabilitation has been an additional intervention in the management of symptoms and hospital admission rates to improve the quality of life and longevity for these patients. The implementation of heart failure-based non-pharmacological interventions in cancer therapy care and rehabilitation for the management of cardiotoxicity may reduce the incidence of cardiotoxic heart failure, cancer tumor recurrence, hospital admissions, thus improving quality of life and survival rates for cancer patients with cardiotoxicity.
Non-pharmacological lifestyle interventions
Evidence-based practice guidelines currently exist for after discharge management for both heart failure and cancer.9,62-64 Many of these guidelines currently target the management of disease-related fatigue, depression and anxiety.65 These guidelines are aimed at older cancer survivors, failing to target childhood cancer survivors potentially facing a compromised quality of life as a result of cardiotoxicity.65 Many of the key messages for healthy eating, activity and wellbeing are the same for preventing heart failure and cancer.9,66-68 Evidence-based practice guidelines currently exist for the after discharge management for both heart failure and cancer patients, with many of these key messages targeting healthy eating, increasing physical activity and improving wellbeing. As the combination of a poor diet, lack of exercise, smoking and excessive alcohol consumption increases the risk of cancer and cardiovascular disease, lifestyle interventions focused on these aspects may potentially counteract the adverse effects of cancer therapy, disease progression or relapse, and may reduce the risk cardiovascular disease.9,67,69,70 A diagnosis of cancer may provide multidisciplinary teams with a window of opportunity for "teachable moments" to guide cancer survivors towards reduced rates of remission, progression of cardiotoxicity and improved overall health and wellbeing as the aim of cardiac rehabilitation programs.71-75
Cardiac rehabilitation
For HF patients, cardiac rehabilitation has been an additional intervention in the management of signs, symptoms and hospital admission rates to improve the quality of life and longevity for these patients. The implementation of heart failure-based non-pharmacological interventions in cancer therapy care and rehabilitation for the management of cardiotoxicity may reduce the incidence of cardiotoxic heart failure, cancer tumor recurrence, hospital admissions, thereby improving quality of life and survival rates for cancer patients with cardiotoxicity.
Exercise
For heart failure patients, the inclusion of physical and dietary modifications with pharmacological management has improved cardiac symptoms, exercise capacity (VO2) and left ventricular function.22,76,77 For cancer survivors, research demonstrates the abundance of positive benefits of exercise such as increasing muscle strength and cardiovascular fitness, lowering blood pressure and reducing fatigue.78-82 Furthermore, the six-minute walk test has been integrated into clinical practice as an additional measure to assess exercise tolerance, functional exercise capacity, and global and integrated responses from all body systems.129 Whilst such interventions are recommended for recovery from cancer care and cardiac rehabilitation, exercise rehabilitation is inconsistently incorporated for the management and/or prevention of cardiotoxicity.74,83 Through a basic scoping search, studies appear to focus predominantly on the impact of exercise on quality of life for cancer survivors, and whilst these are significantly important in this population, there is limited research on the impact of exercise on cardiotoxicity.57,84-86
Dietary modifications
Obesity is an increasingly prevalent metabolic disorder and with an increased link to cancer, obesity remains a modifiable risk factor for both cardiovascular disease and cancer.130,131 Diet and exercise are interventions which are commonly combined and known for preventing of cardiovascular disease and some cancers, and improving general health, wellbeing and cancer survivorship.7,67,73,87 Several cohort studies have alluded to the positive outcomes of dietary modification clinical trials in reducing cholesterol and blood pressure in HF patients.89 Of significant interest is whether the implementation of nutritional guidelines from the Australian Heart Foundation can reduce the risk of cardiotoxicity by targeting cardiovascular risk factors, such as hypertension and high cholesterol.89,90,122 To the knowledge of the authors, studies on nutritional interventions and cancer are present from low level evidence; therefore current practice lacks evidence-based nutritional guidelines on the management or prevention of cardiotoxicity in humans.92-94
Alcohol modifications
For adults, moderate alcohol intake has shown a cardioprotective effect in secondary prevention of heart disease; however, alcohol has been identified as an independent risk factor in cancers of the head and neck.96-98,123 In childhood or adolescent cancer patients, excessive alcohol consumption has the ability to interfere with cell membranes and compromise cell integrity, with a negative impact on survival.97 With up to 75% of head and neck cancers attributed to the combination of alcohol consumption and smoking, clinical practice guidelines for the role of cardioprotection by alcohol are yet to be developed, warranting further research.98,100,101
Cessation of smoking
Cigarette smoking is considered an independent risk factor for the development of HF and accounts for up to 30% of all cancer deaths in the general population.5,20,103,104,124 Associated with a significantly advanced tumor grade at diagnosis and a higher recurrence rate of relapse from primary or secondary tumors, smoking is notably a modifiable risk health behavior linked to negative outcomes in cancer survivorship.5,7,66 Despite the known damaging effects of smoking, 17 to 30% of childhood cancer survivors smoke throughout the survivorship stages.105 While cessation of smoking should be encouraged in patients facing potential cardiotoxic cancer therapies, further research is required to ascertain the effects of smoking on the development of cardiotoxicity and to provide rigorous and supportive strategies to maintain tobacco abstinence.104
Complementary and alternative medicine
Complementary and alternative medicine (CAM) is becoming increasingly popular among cancer patients in conjunction with conventional medical management.106-109 Defined as therapies not regarded as conventional medicine, such as yoga, meditation and massage, up to 90% of hospitalized cancer patients seek CAM to enhance wellbeing, quality of life and chances of survival, and to reduce the risk of cancer recurrence and cancer treatment associated side effects.106,108-116,119 For HF patients, the ability for these alternative therapies to positively impact on reducing distress, blood pressure and cardiac mortality has been well-established; however, these are limited to cardiac rehabilitation programs for unknown reasons.111,115 Furthermore the combination of these alternative approaches may in turn decrease depression, stress and anxiety, inadvertently targeting cardiac risk factors.22,32,110-117 Currently, literature does provide evidence of the improvements in quality of life for both cancer and cardiac patients; however the effects of mindfulness-based stress reduction techniques, such as yoga, massage and meditation, are yet to be determined in the management of cardiotoxicity when incorporated with other lifestyle changes.
An initial review of the literature suggests there is substantial evidence on the incidence of cardiotoxicity amongst cancer patients as a result from cancer therapies. However, there is developing research which justifies the implementation of non-pharmacological interventions in the care of cancer patients to improve patient outcomes; however gaps remain within research and evidence-based practice strategies for the aftercare of patients who have developed cardiotoxicity after cancer treatment. Therefore, this systematic review will investigate the evidence on the management of cardiotoxicity and the role of non-pharmacological interventions.
Inclusion criteria
Types of participants
This review will consider any studies that include patients, irrespective of age or gender, diagnosed with any type of cancer, who are treated with chemotherapy and/or radiotherapy, with or without an additional surgical intervention, and diagnosed with a cardiac complication as a result of that treatment. Studies will be included regardless of active or previous cancer therapy undertaken by participants prior to involvement with the study intervention(s). Non-English language studies will be assessed by scientific translation services if required and included, based on inclusion criteria.
Types of intervention(s)
The types of interventions to be eplored in this review are non-pharmacological interventions for cardiac function and may include but are not limited to:
* Cardiac rehabilitation
* Exercise
* Cessation of smoking
* Dietary modifications
* Meditation
* Yoga
* Massage
Comparator
Participants who were offered standard care for the ongoing management cancer and/or heart failure.
Types of outcomes
This review will consider studies that include the following outcome measures
Primary outcomes (changes to cardiac function):
* Primary signs of heart failure such as shortness of breath and changes in resting heart rate measured by beats per minute
* VO2MAX measured by peak expiratory volume (ml/kg/min or L/min) during exercise test on cycle ergometer or treadmill
* Six-minute walk test measuring the total distance in steps or meters walked in six minutes measuring aerobic capacity
* Body Mass Index as measured by approved body composition analyzer or manual calculation (height [kg]/weight [cms]2).
Secondary outcomes:
* Quality of life measured by any of the following; European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C-30, Functional Assessment of Cancer Therapy-Breast (FACT-B) Scale, Functional Assessment of Cancer Therapy-General (FACT-G) Scale, Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale, Functional Assessment of Cancer Therapy-Prostate (FACT-P) Scale, Kansas City Cardiomyopathy Questionnaire.
* Lean Body Mass by Dual X-ray Absorption method or by the following formula; body mass-fat mass then converted to a percentage.
* Waist Circumference by measuring the narrowest part of the torso at the level of the umbilicus
* Body weight measured by approved scales.
Types of studies
This review will consider experimental study designs including randomized controlled trials, non-randomized controlled trials and quasi-experimental studies, which evaluate the effectiveness of non-pharmacological interventions on cancer treatment induced cardiotoxicity.
Search strategy
The search strategy aims to find both published and unpublished studies in English. A multi-step search process will be used considering only English written articles published from January 1970 up to January 2015.128 An initial limited search of MEDLINE and CINAHL will be undertaken followed by an analysis of the text words contained in the titles and abstracts of relevant papers, as well as their subject headings. A second search using all identified text words and subject headings will then be undertaken using all included databases, as well as the Google Scholar search engine. Thirdly, we will search for grey literature using the Google search engine and by checking for "deep web" content within the websites of relevant organizations. Finally, the reference lists of all relevant papers identified will be searched for additional studies and prevalent authors contacted to identify additional unpublished studies.128
The databases to be searched include:
Medline (OvidSP)
Embase (OvidSP)
Cochrane Central Trials Register
CINAHL
ProQuest (health subset)
Informit (health subset)
Scopus
Web of Science.
The search for unpublished studies will include:
TROVE
Networked Digital Library of Theses and Dissertations (NDLTD)
PQDT Open
World Health Organization
National Institute for Health and Care Excellence (NICE)
NHMRC
National Institute of Clinical Studies (NICS)
clinicaltrials.gov
Open-Grey
Grey Literature Report
relevant conference/congress websites
Google (advanced search)
Google Scholar.
Initial keywords to be used will be:
cardiotoxicity, cardiomyopathy, heart failure, cardioprotection, cardiac rehabilitation, cardiotoxic stress, cancer, cancer care, oncology, anthracycline, tratzusumab, chemotherapy, antineoplastic agents, radiotherapy, chest irradiation, non-pharmacological, diet, dietary supplementation, exercise, running, sports, smoking cessation, yoga, dance, relaxation, massage, meditation
Assessment of methodological quality
Papers selected for retrieval will be assessed by two independent reviewers for methodological validity prior to inclusion in the review using standardized critical appraisal instruments from the Joanna Briggs Institute Meta Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI) (Appendix I). Any disagreements that arise between the reviewers will be resolved through discussion, or with a third reviewer.
Data extraction
Data will be extracted from papers included in the review using the standardized data extraction tool from JBI-MAStARI (Appendix I). The data extracted will include specific details about the interventions, populations, study methods and outcomes of significance to the review question and specific objectives.
Data synthesis
Quantitative data will, where possible be pooled in statistical meta-analysis using JBI-MAStARI. All results will be subject to double data entry. Effect sizes expressed as weighted mean differences (for continuous data) and their 95% confidence intervals will be calculated for analysis. Heterogeneity will be assessed statistically using the standard Chi-square and also explored using subgroup analyses based on the different study designs included in this review. Where statistical pooling is not possible the findings will be presented in narrative form including tables and figures to aid in data presentation where appropriate.
Conflicts of interest
The authors declare that there is no conflict of interest.
Acknowledgements
No external funding is involved in this review. This systematic review will contribute to the primary reviewer's Honors degree at Flinders University, Adelaide, South Australia.
References
1. Yeh E, Bickford C. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53: 2231-2247. [Context Link]
2. Colombo A, Cardinale D. Using cardiac biomarkers and treating cardiotoxicity in cancer. Future cardiology 2013; 9: 105-118. [Context Link]
3. Yu X, Prosnitz R, Zhou S, HardenberghP, Tisch A, Blazing M et al. Symptomatic cardiac events following radiation therapy for left-sided breast cancer: possible association with radiation therapy-induced changes in regional perfusion. Clinical Breast Cancer 2003; 4: 193-197. [Context Link]
4. Smiseth O, Edvardsen T, Skulstad H. Cardioprotection During ChemotherapyNeed for Faster Transfer of Knowledge From Cardiology to Oncology and Role for a Cardio-Oncologist. J Am Coll Cardiol 2013; 61: 2363-2364. [Context Link]
5. Gajdos C, Hawn M, Campagna E, Henderson W, Singh J Houston T. Adverse effects of smoking on postoperative outcomes in cancer patients. Ann of Surg Oncol 2012; 19: 1430-1438. [Context Link]
6. Hunt S, Abraham W, Chin M, Feldman A, Francis G, Ganiats et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation. Endorsed by the Heart Rhythm Society. Circulation 2005;1-55. [Context Link]
7. Rao A, Demark-Wahnefried W. The older cancer survivor. Critical reviews in oncology/hematology 2006; 60: 131-143. [Context Link]
8. Olivera G, Dupont M, Naftel D, Meyers S, Yuan Y, Tang W et al. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS registry (Interagency Registry for Mechanically Assissted Circulatory support) J Am Coll Cardiol 2014; 63: 240-8. [Context Link]
9. Murthy V, Chamberlain R. Menospausal symptoms in young survivors of breast cancer: a growing problem without an ideal solution. Cancer Control 2012; 19: 317-29. [Context Link]
10. Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced Cardiotoxicity. Maedica 2013; 8: 59-67. [Context Link]
11. Cardinale D, Colombo A, Sandri M, Lamantia G, Colombo N, Civelli M et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circ 2006; 114: 2474-81. [Context Link]
12. Hasin T, Gerber Y, Weston S, Killian J, McNallan S, Cerhan J et al. Heart failure after myocardial infarction is associated with increased risk of cancer. J AmColl Cardio 2014; 63: 953. [Context Link]
13. Callender T, Woodward M, Roth G, Farzadfar F, Lemarie J, Gicquel S et al. Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. PLoS Medicine 2014; 11: 249-256. [Context Link]
14. McDonagh T, Garnder R, Lainscak M, Neilsen O, Parissis J, Filippatos G et al. Heart failure association of the European Society of Cardiology specialist heart failure curriculum. Euro J of Heart Failure 2014; 16: 151-62. [Context Link]
15. Viale P, Yamamoto D. Cardiovascular toxicity associated with cancer treatment. Clin J of Oncology Nurs 2008; 12: 627-38. [Context Link]
16. Hunt A, Abraham, W, Chin M, Feldman A, Francis Gm Ganiats T et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Chest Physicians and the interantional Society for Heart and Lung Transplantation. Circ 2005; 112:154-235. [Context Link]
17. Inlgis S. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. J of Evidence based Med 2010; 3: 228-235. [Context Link]
18. Inglis S, Clark R, McAlister F, Stewart S, Cleland J. Which components of heart failure programmes are effective? A systematic review and meta-analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure managment in 8323 patients: Abridged Cochrane Review. Euro J of heart failure 2011; 13: 1028-40. [Context Link]
19. Tang W, Francis G. The year in hear failure. J Am Coll Cardiol. 2006; 48: 2575-83. [Context Link]
20. Lip G, Gibbs C, Beevers D. ABC of heart failure; aetiology. BMJ 2000; 320: 104. [Context Link]
21. Adams M, Lipsitz S, Colan S, Tarbell N, Treves S, Diller L et al. Cardiovascular status in long-term survivors of Hodkins disease treated with chest radiotherapy. J Clin Oncol 2004; 22: 3139-48. [Context Link]
22. Beckie T, Beckstead J, Kip K, Fletcher G. Improvements in heart rate recovery among women after cardiac rehabilitaiton completion. J Cardiovasc. Nurs 2014; 29: 38-47. [Context Link]
23. Clark R, Conway A, Poulsen V, Keech W, Tirimacco R, Tideman P. Alternative models of cardiac rehabilitation: a systematic review. Euro J of Prevent Cardiol. 2013; 5: 322-337. [Context Link]
24. Balady G, Williams M, Ades P, Bittner V, Comoss P, Foody J et al. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update a scientific statement from the American heart Association Exercise, Cardiac Rehabilitation and Prevention committee, the Council on clinical Cardiology; Councils on Cardiovascular Nursing, epidemiology and prevention, nutrition and physical activity and metabolism; and the American Associatioin of Cardiovascular and Pulmonary Rehabilitation. Circ 2007; 115: 2675-82. [Context Link]
25. Inglis S, Conway A, Cleland J, Clark R. Is age a factor in the success or failure of remote monitoring in heart failure? Telemonitoring and structured telephone support in elderly heart failure paitents. Euro J of Cardiovasc Nurs 2014; 1-26. [Context Link]
26. Wenger N. Cardiac rehabilitation. Cardiovasc Prev and Rehab 2007; 34: 1-11 [Context Link]
27. Cancer Australia. Cancer Australia strategic plan 2011-2014. Sydney NSW: Cancer Australia 2011. [Context Link]
28. Daher I, Diagle T, Bhatia N, Durand J. The prevetion of cardiovascular disease in cancer survivors. Texas Heart Institute J 2012; 36: 190. [Context Link]
29. Bonita R, Pradhan R. Cardiovascular toxicities of cancer chemotherapy. Sim Oncol 2013; 40: 156-167. [Context Link]
30. Bonifazi M, Franchi M, Rossi M, Moja L, Zambelli A, Zambon A et al. Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study. The Oncologist 2013; 18: 795-801. [Context Link]
31. Berardi R, Caramanti M, Savini A, Chiorrini S, Pierantoni C, Onofri A et al. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: A literature review. Critical reviews in oncol/haem 2013; 88: 75-86. [Context Link]
32. Todaro M, Oreto L, Qamar R, Paterick T, Carerj S, Khandheri B. Cardioncology: State of the heart. Int J Cardiol 2013; 168: 680-687. [Context Link]
33. Yeh, E Bickford C. Cardiovascular complications of cancer therapy diagnosis, pathogenesis, and management. J Am Coll Cardiol 2009; 53: 2231-47. [Context Link]
34. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer treatment reviews 2011; 37: 300-11. [Context Link]
35. Jensen S, Hasback P, Mortensen J, Sorensen J. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol 2010; 28: 5280-6. [Context Link]
36. Lestuzzi C. Cardioncology, oncocardiology. Are we barking up the wrong tree? Int J Cardiol 2013; 167: 307-9. [Context Link]
37. Onitilo A, Engle J, Stankowski R. Cardiovascular toxicity with adjuvant trastuzumab: prevalence, patient characteristics and risk factors. Ther Adv in Drug Safety 2014; 1:1-16. [Context Link]
38. Steingart R, Yadav N, Manrique C, Carver J, Liu J. Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management. J Semin Oncol 2013: 40: 690-708. [Context Link]
39. Australian Institute of Health and welfare. Radiation oncology areas of need: cancer incidence projections 2014-2024. Canberra ACT: Australian Institute of Health and Welfare, 2014 Report no. CAN 82. [Context Link]
40. Khakoo A, Yeh T. Therapy insight: manamgent of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol 2008; 5:655-67. [Context Link]
41. Huang Y, Lee C, Chant T, Ho H, Su Y, Hung S et al. Increased risk of stroke in young head and nexk cancer patients treated with radiotherapy or chemotherapy. Oral Oncol 2011; 5:1092-7. [Context Link]
42. Mainko T, Dolenc J, Bilban-Jakopin C. Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer. Radio and Oncol 2014; 48:102-12. [Context Link]
43. Tait L, Meyer J, McSpadden E, Cheng J, Baciewicz F, Meropol N et al. Women at increased risk for cardiac toxicity following chemoradiation therapy for esophageal carcinoma. Prac radiat Oncol 2013; 3:149-55. [Context Link]
44. Lestuzzi C. Cardioncology, oncocardiology. Are we barking up the wrong tree? Int J Cardiol 2013; 167: 307-9. [Context Link]
45. Stone H, Coleman C, Anscher M, McBride W. Effects of radiation on normal tissue: consequences and mechanism. The lancet Oncol 2003; 4: 529-36. [Context Link]
46. Adams M, Lipshultz S, Schwarts C Fajardo L, Coen V, Constine L. Radiation-assocaited cardiovascular disease: Manifestations and management. Sem in Rad Oncol 2003; 13: 345-56. [Context Link]
47. Peterson C, Wurschmidt F. Late toxicity of radiotherapy: a problem or a challenge for the radiation oncologist? Breast Care 2011; 6: 369-74. [Context Link]
48. Wong C, Hawkins N, Petrie M, Jhund P, Gardner R, Ariti C et al. Heart failure in younger patients: the Meta-Analysis Global Group in Chronic Heart Failure (MAGIC). Euro Heart J 2014; 42: 1-26. [Context Link]
49. Yeh J, Nohria A, Diller L. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and econonmic effects. Ann Intern Med 2014; 160: 661-71. [Context Link]
50. Jensen B, Skovsgaard T, Nielsen S. Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. The Lancet 1996;347: 297-9. [Context Link]
51. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48:2258-62. [Context Link]
52. Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study. Int J Cardiol 2013; 167: 2306-10. [Context Link]
53. Swain S, Whaley F, Gerber M, Weisberg S, York M, Spicer D, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15: 1318-32. PMid:9193323 [Context Link]
54. Wouters K, Kremer L, Miller T, Herman E, Lipshultz S. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. British J of haem 2005; 131: 561-78 [Context Link]
55. Popelova O, Sterba M, Haskova P, Simanek T, Hroch M, Guncova I, et al. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. British J of cancer 2009; 101: 792-802. [Context Link]
56. Hellbom M, Bergelt C, Bergenmar M, Gijsen B, Loge J, Rautalathi M, et al. Cancer rehabilitation: a nordic and european perspective. Acta Oncol 2011; 50: 179-86. [Context Link]
57. Adamsen L, Quist M, Andersen C, Moller T, Herrstedt J, Kronborg D, et al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ 2009; 339: 1-11. [Context Link]
58. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 11: 2474-81. [Context Link]
59. Courneya K, Friedenreich C, Quinney H, Fields A, Jones L, Fairey A. A randomized trial of exercise and quality of life in colorectal cancer survivors. Eur J Cancer Care 2003; 12: 347-57. [Context Link]
60. Steingart R, Yadav N, Manrique C, Carver J, Liu J. Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management. Semin Oncol 2013; 40: 690-708. [Context Link]
61. McMurray J, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000; 83: 596-602. [Context Link]
62. Alfano C, Ganz P, Rowland J, Hahn E. Cancer survivorship and cancer rehabilitation: revitalizing the link. J Clin Oncol 2012; 30: 904-6. [Context Link]
63. Easley J, Miedema B. Rehabilitation after breast cancer: recommendations from young survivors. Rehab Nurs 2012; 37: 163-70. [Context Link]
64. Warburton D, Nicol C, Bredin S. Health benefits of physical activity: the evidence. Canadian Med Assoc J. 2006; 174: 801-9. [Context Link]
65. Murthy V, Chamberlain R. Menopausal symptoms in young survivors of breast cancer: a growing problem without an ideal solution. Can Cont 2012; 19: 317-29. [Context Link]
66. Rowland J, Bellizzi K. Cancer Survivorship Issues: Life After Treatment and Implications for an Aging Population. J Clin Oncol 2014; 32: 2662-8. [Context Link]
67. Bellury L, Ellington L, Beck SL, Stein K, Pett M, Clark J. Elderly cancer survivorship: An integrative review and conceptual framework. Eur J Oncol Nurs 2011; 15: 233-42. [Context Link]
68. Dossus L, Kaaks R. Nutrition, metabolic factors and cancer risk. Best practice & research clinical endocrin & metabol. 2008; 22: 551-71. [Context Link]
69. Spence R, Heesch K, Brown W. Exercise and cancer rehabilitation: a systematic review. Cancer treat reviews 2010; 36: 185-94. [Context Link]
70. Davies N, Batehup L, Thomas R. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature. British J of cancer 2011; 105: 52-73. [Context Link]
71. La Forge R. Mind-body fitness: encouraging prospects for primary and secondary prevention. J Cardiovasc Nurs 1997; 11: 53-65. [Context Link]
72. Gies C, Buchman D, Robinson J, Smolen D. Effect of an inpatient nurse-directed smoking cessation program. Western J of nurs research 2008; 30: 6-19. [Context Link]
73. Moller T, Lillelund C, Andersen C, Ejlertsen B, Norgaard L, Christensen KB, et al. At cancer diagnosis: a 'window of opportunity' for behavioural change towards physical activity. A randomised feasibility study in patients with colon and breast cancer. BMJ 2013; 1-12. [Context Link]
74. Toles M, Demark-Wahnefried W. Nutrition and the cancer survivor: evidence to guide oncology nursing practice. Sem Oncol Nurs 2008; 3: 171-9. [Context Link]
75. Feuerstein M, Gehrke A, Wronski S, Oldham K. The journal of cancer survivorship: informing health care providers and cancer survivors. J of Cancer Survivorship 2014; 8: 151-5. [Context Link]
76. Cheville A. Cancer rehabilitation. Semin Oncol 2005; 32: 219-224. [Context Link]
77. Iarussi D, Indolfi P, Galderisi M, Bossone E. Cardiac toxicity after anthracycline chemotherapy in childhood. Herz 2000; 25: 676-88. [Context Link]
78. Meyer P, Gayda M, Juneau M, Nigam A. High-intensity aerobic interval exercise in chronic heart failure. Current heart failure reports 2013; 10: 130-8. [Context Link]
79. Basen-Engquist K, Taylor C, Rosenblum C, Smith M, Shinn E, Greisinger A et al. Randomized pilot test of a lifestyle physical activity intervention for breast cancer survivors. Patient Education and Counseling 2006; 64: 225-34. [Context Link]
80. Jones L, Haykowsky M, Swartz J, Douglas P, Mackey J. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007; 50: 1435-41. [Context Link]
81. Demark-Wahnefried W, Clipp E, Morey M, Pieper C, Sloane R, Snyder D et al. Physical function and associations with diet and exercise: Results of a cross-sectional survey among elders with breast or prostate cancer. Internat J Behav Nutrit and Phys Act 2004; 1:16. [Context Link]
82. Speck R, Courneya K, Masse L, Duval S, Schmitz K. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Survivorship 2010; 4: 87-100. [Context Link]
83. Bruun D, Bjerre E, Krustrup P, Brasso K, Johansen C, Rorth M et al. Community-based recreational football: a novel approach to promote physical activity and quality of life in prostate cancer survivors. Internat J environ research and public health 2014; 11: 5567-85. [Context Link]
84. Stevinson C, Lawlor D, Fox K. Exercise interventions for cancer patients: systematic review of controlled trials. Cancer Causes Control 2004; 15: 1035-56. [Context Link]
85. Courneya K, Segal R, Mackey J, Gelmon K, Reid R, Friedenreich C et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol 2007; 25: 4396-404. [Context Link]
86. Courneya K, Sellar C, Stevinson C, McNeely M, Peddle C, Friedenreich C et al. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol 2009; 27: 4605-12. [Context Link]
87. Thorsen L, Skovlund E, Stromme S, Hornslien K, Dahl A, Fossa S. Effectiveness of physical activity on cardiorespiratory fitness and health-related quality of life in young and middle-aged cancer patients shortly after chemotherapy. J Clin Oncol 2005; 23: 2378-88. [Context Link]
88. Rao A, Demark-Wahnefried W. The older cancer survivor. Critical reviews in oncol/hemat 2006; 60: 131-43.
89. Voipio-Pulkki L. Feasibility of, and success in adopting a low-fat diet in coronary patients. Scand J Rehab Med 2000; 32: 180-6. [Context Link]
90. Holmes A, Sanderson B, Maisiak R, Brown A, Bittner V. Dietitian services are associated with improved patient outcomes and the MEDFICTS dietary assessment questionnaire is a suitable outcome measure in cardiac rehabilitation. J Am Diet Assoc 2005; 105: 1533-40. [Context Link]
91. Krauss R, Eckel R, Howard B, Appel L, Daniels S, Deckelbaum R et al. AHA dietary guidelines revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circ 2000; 102: 2284-99.
92. Demark-Wahnefried W, Rock C. Nutrition-related issues for the breast cancer survivor. Semin Oncol 2003; 30: 789-98. [Context Link]
93. Rock C, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya K, Schwartz A et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012; 62: 242-74. [Context Link]
94. Rock E, DeMichele A. Nutritional approaches to late toxicities of adjuvant chemotherapy in breast cancer survivors. J Nutr 2003; 133: 3785-93. [Context Link]
95. van Dalen E, van der Pal H, Caron H, Kremer L. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database of Systematic Reviews 2009;1-38.
96. Anthony D, George P, Eaton C. Cardiac risk factors: environmental, sociodemographic, and behavioral cardiovascular risk factors. FP essentials 2014; 421: 16-20. PMid:24936715 [Context Link]
97. Hanf V, Gonder U. Nutrition and primary prevention of breast cancer: foods, nutrients and breast cancer risk. Euro J of Obstetrics & Gyne and Repro Bio 2005; 123: 139-49. [Context Link]
98. Broglie M, Soltermann A, Rohrbach D, Haile S, Pawlita M, Studer G et al. Impact of p16, p53, smoking, and alcohol on survival in patients with oropharyngeal squamous cell carcinoma treated with primary intensity-modulated chemoradiation. J Head & neck 2013; 35: 1698-706. [Context Link]
99. Abramson J, Williams S, Krumholz H, Vaccarino V. Moderate alcohol consumption and risk of heart failure among older persons. JAMA 2001; 285: 1971-7.
100. Patane S. Cardiotoxicity: Anthracyclines and long term cancer survivors. Int J Cardiol 2014; 176: 1326-28. [Context Link]
101. Patane S. Cardiotoxicity: Trastuzumab and cancer survivors. Int J Cardiol 2014; 177: 554-6 [Context Link]
102. Gajdos C, Hawn M, Campagna E, Henderson W, Singh J, Houston T. Adverse effects of smoking on postoperative outcomes in cancer patients. Ann Surg Oncol 2012; 19: 1430-8.
103. Kenfield S, Stampfer M, Chan J, Giovannucci E. Smoking and prostate cancer survival and recurrence. Jama 2011; 305: 2548-55. [Context Link]
104. Park E, Japuntich S, Rigotti N, Traeger L, He Y, Wallace R et al. A snapshot of smokers after lung and colorectal cancer diagnosis. Cancer 2012; 118: 3153-64. [Context Link]
105. Ford JS, Puleo E, Sprunck-Harrild K, Demoor J, Emmons KM. Perceptions of risk among childhood and young adult cancer survivors who smoke. Support Care Cancer 2014; 22: 2207-17 [Context Link]
106. Hunter D, Oates R, Gawthrop J, Bishop M, Gill S. Complementary and alternative medicine use and disclosure amongst Australian radiotherapy patients. Supp Care Cancer 2014; 22: 1571-8. [Context Link]
107. Tacon A. Meditation as a complementary therapy in cancer. Fam Comm Health 2003; 26: 64-73. [Context Link]
108. Wilkinson J, Stevens M. Use of complementary and alternative medical therapies (CAM) by patients attending a regional comprehensive cancer care centre. J Complem & Integ Med 2014; 11: 139-45. [Context Link]
109. Zhu Y, Romitti PA, Conway K, Andrews J, Liu K, Meaney F et al. Complementary and Alternative Medicine for Duchenne and Becker Muscular Dystrophies: Characteristics of Users and Caregivers. Ped neurol 2014; 51: 71-7. [Context Link]
110. Park C, Cho D, Wortmann J. The impact of Yoga upon young adult cancer survivors. Comp Ther Clin Pract 2013; 19: 77-82. [Context Link]
111. van Dixhoorn J, White A. Relaxation therapy for rehabilitation and prevention in ischaemic heart disease: a systematic review and meta-analysis. Euro J of Cardiovasc Prev & Rehab 2005; 12: 193-202. [Context Link]
112. Clark P, Cortese-Jimenez G, Cohen E. Effects of Reiki, Yoga, or Meditation on the Physical and Psychological Symptoms of Chemotherapy-Induced Peripheral Neuropathy A Randomized Pilot Study. J Evidence-Based Comp & Altern Medicine 2012; 17: 161-71. [Context Link]
113. Dhruva A, Miaskowski C, Abrams D, Acree M, Cooper B, Goodman S et al. Yoga Breathing for Cancer Chemotherapy-Associated Symptoms and Quality of Life: Results of a Pilot Randomized Controlled Trial. J Altern & Comp Med 2012; 18: 473-9. [Context Link]
114. Jayasinghe S. Yoga in cardiac health (a review). Euro J of Cardiovasc Prev & Rehab 2004; 11: 369-75. [Context Link]
115. Jayaram N, Arnold S, Gosch K, Buchanan D, Decker C, Kosiborod M. The association between complementary and alternative medicine and health status following acute myocardial infarction. J Am Coll Cardiol 2014; 63: 12-24. [Context Link]
116. Krishna B, Pal P, Pal G, Balachander J, Jayasettiaseelon E, Sreekanth Y et al. Effect of Yoga Therapy on Heart Rate, Blood Pressure and Cardiac Autonomic Function in Heart Failure. J clin and diag research 2014; 8: 14-16. PMid:24596712 PMCid:PMC3939525 [Context Link]
117. Yang X, Zhao H, Wang J. Chinese massage (Tuina) for the treatment of essential hypertension: A systematic review and meta-analysis. Compl Ther in Med 2014; 22: 541-8. [Context Link]
118. Xiong X, Li S, Zhang Y. Massage therapy for essential hypertension: a systematic review. J human hypertension 2014; 22: 541-48.
119. Raghavendra R, Nagarathna R, Nagendra H, Gopinath K, Srinath B, Ravi B et al. Effects of an integrated yoga programme on chemotherapy-induced nausea and emesis in breast cancer patients. Eur J Cancer Care 2007; 16: 462-74. [Context Link]
120. Gerrish K, Lacey A. The research process in nursing, 6th edn UK: Wiley & Sons, 2010
121. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (Chronic Heart Failure Expert Writing Panel). Guidelines for the prevention, detection and management of chronic heart failure in Australia. Updated October 2011; 1-86. [Context Link]
122. Australian Government Department of Health and Ageing. Food for Health; dietary guidelines for Australians - a guide to healthy eating. National Health and Medical Research Council 2005: 1-28. [Context Link]
123. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Reducing risk in heart disease: an expert guide to clinical pratice for secondary prevention of coronary artery disease. Melbourne, National Heart Foundation of Australia, 2012: 2-20. [Context Link]
124. Ho K, Pinsky J, Kannel W, Levy D, Pitt B. The epidemiology of heart failure: the framinham study. JACC 1993; 22: 6-13. [Context Link]
125. Chow E, Chen Y, Leontien C, Kremer C, Breslow N, Hudon M et al. Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol 2014; 32: 1-15. [Context Link]
126. Walker J, Sharma A, Lytwyn M, Bohonis S, Thliveris J, Singal P et al. The cariodprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity. J Am Soc Echo 2011; 24: 699-705. [Context Link]
127. Colombo A, Meroni C, Cipolla C, Cardinale D. Managing cardiotoxicity of chemotherapy. Curr Treat Opt Cardiovasc Med 2013; 14: 410-424. [Context Link]
128. Joanna Briggs Institute. Joanna Briggs Institute reviewers' manual: 2014 edn. Adelaide, Australia, JBI. [Context Link]
129. Americn Thoracic Society. ATS Statement: Guidelines for the Six-Minute Walk Test. American J of resp and crit care med 2002; 166: 111-7 [Context Link]
130. Kruijsdijk C, van der Wall E, Visseren F. Obesity and Cacner: The Role of Dysfunctional Adipose Tissue. Cancer Epidemiology, Biomarkers & Prevention 2009; 18: 2569 [Context Link]
131. Eckel H. Obesity and Heart Disease: A statement for Healthcare Professionals From the Nutrition Committee, American Heart Association. Circulation 1997; 96: 3248-3250 [Context Link]
Appendix I: Appraisal instruments
MAStARI appraisal instrument[Context Link]
Appendix II: Data extraction instruments
MAStARI data extraction instrument
Keywords: cardiotoxicity; heart failure; chemotherapy; radiotherapy; systematic review